Free tool
FAERS Monitor: Leqembi Iqlik
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761375 or its brand name (Leqembi Iqlik, Lecanemab-Irmb). Reports on generic versions are filed under their own applications.
Reports
17
Serious
9
53% of reports
Hospitalization
4
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- infusion related reaction6
- headache5
- chills4
- dizziness3
- hypoaesthesia3
- muscular weakness3
- amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits2
- arthralgia2
- asthenia2
- fall2
- myalgia2
- pyrexia2
- sedation2
- tremor2
- vomiting2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 8 |
| 2025 | 5 |
| 2026 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,142 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits | 2 | 2312.8 | 628.3 | 2,594 |
| infusion related reactionSignal | 6 | 112.0 | 58.8 | 555 |
| sedation | 2 | 94.5 | 25.7 | 103 |
| chillsSignal | 4 | 42.2 | 17.9 | 123 |
| muscular weaknessSignal | 3 | 32.7 | 11.7 | 63 |
| hypoaesthesiaSignal | 3 | 24.8 | 8.9 | 47 |
| tremor | 2 | 14.9 | 4.1 | 14 |
| myalgia | 2 | 14.6 | 4.0 | 14 |
| headacheSignal | 5 | 9.9 | 4.7 | 32 |
| dizzinessSignal | 3 | 7.4 | 2.7 | 11 |
| fall | 2 | 7.4 | 2.0 | 6 |
| pyrexia | 2 | 7.2 | 1.9 | 5 |
| asthenia | 2 | 6.6 | 1.8 | 5 |
| arthralgia | 2 | 6.0 | 1.6 | 4 |
| vomiting | 2 | 5.3 | 1.4 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.